Watch out Eli Lilly, AbbVie and Biogen: 7 new blockbusters are on their way to shake things up
Every year a select group of new drugs promise not to just add an extra option for patients. Some of these blockbuster-to-be drugs are expected to dramatically reshape existing markets, often by stealing away more than their share from the therapies that already dominate in a field.
Here are 7 being billed as blockbuster buster.
The analysts at Cortellis didn’t just forecast 2023 sales for the most promising new drugs slated to win an approval this year, or already prepped for launch. They also calculated how they would do against the dominant drugs in their class. And many times their success will weigh heavily on the chart-topping drugs in their field.
Here’s a summary, based on the new report.
Basic subscription required
Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.